The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Abeona Therapeutics Inc (NASDAQ: ABEO) closed at $5.0 down -1.57% from its previous closing price of $5.08. In other words, the price has decreased by -$1.57 from its previous closing price. On the day, 0.85 million shares were traded. ABEO stock price reached its highest trading level at $5.1199 during the session, while it also had its lowest trading level at $5.0.
Ratios:
For a deeper understanding of Abeona Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.53 and its Current Ratio is at 9.74. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.09.
On March 05, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $16.
On July 03, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $15.H.C. Wainwright initiated its Buy rating on July 03, 2024, with a $15 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 13 ’25 when Alvino Mark sold 15,000 shares for $4.74 per share. The transaction valued at 71,168 led to the insider holds 62,252 shares of the business.
Alvino Mark bought 15,000 shares of ABEO for $71,168 on Nov 13 ’25. On Oct 16 ’25, another insider, Seshadri Vishwas, who serves as the Chief Executive Officer of the company, sold 249 shares for $5.49 each. As a result, the insider received 1,366 and left with 1,189,818 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABEO now has a Market Capitalization of 270956800 and an Enterprise Value of 87946808. As of this moment, Abeona’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 677.39 while its Price-to-Book (P/B) ratio in mrq is 1.53. Its current Enterprise Value per Revenue stands at 219.867 whereas that against EBITDA is -1.086.
Stock Price History:
The Beta on a monthly basis for ABEO is 1.12, which has changed by -0.09769094 over the last 52 weeks, in comparison to a change of 0.16081822 over the same period for the S&P500. Over the past 52 weeks, ABEO has reached a high of $7.54, while it has fallen to a 52-week low of $3.93. The 50-Day Moving Average of the stock is 0.60%, while the 200-Day Moving Average is calculated to be -11.66%.
Shares Statistics:
For the past three months, ABEO has traded an average of 1.71M shares per day and 1400590 over the past ten days. A total of 52.40M shares are outstanding, with a floating share count of 49.46M. Insiders hold about 8.73% of the company’s shares, while institutions hold 62.41% stake in the company. Shares short for ABEO as of 1764288000 were 13812286 with a Short Ratio of 8.09, compared to 1761868800 on 10350316. Therefore, it implies a Short% of Shares Outstanding of 13812286 and a Short% of Float of 27.18.
Earnings Estimates
The dynamic stock of Abeona Therapeutics Inc (ABEO) is currently being evaluated by a team of 3.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.05 and low estimates of -$0.15.
Analysts are recommending an EPS of between $1.33 and -$1.6 for the fiscal current year, implying an average EPS of -$0.14. EPS for the following year is -$0.07, with 3.0 analysts recommending between $0.2 and -$0.36.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $18.67M. There is a high estimate of $24.9M for the next quarter, whereas the lowest estimate is $9.6M. Based on 7 analysts’ estimates, the company’s revenue will be $112.09M in the next fiscal year. The high estimate is $140.3M and the low estimate is $79.84M.
